4/A: Inari Medical Director Cynthia Lucchese Amends Form 4 Filing to Include Power of Attorney

Cynthia Lucchese, a director at Inari Medical, amended her Form 4 filing to include a previously granted Power of Attorney.

Summary

• Cynthia Lucchese, a director of Inari Medical, Inc., filed an amended Form 4 with the SEC.
• The amendment, filed on May 31, 2024, relates to a transaction reported on April 26, 2024.
• The purpose of the amendment is to include a Power of Attorney granted to an attorney-in-fact.
• On April 24, 2024, Lucchese acquired 4,126 shares of common stock at a price of $42.41 per share.
• These shares were granted as restricted stock units, vesting fully on the earlier of the day prior to the next annual meeting or one year from the grant date.
• Following the reported transaction, Lucchese beneficially owns 38,429 shares of Inari Medical common stock.
• The Power of Attorney, executed on July 26, 2023, authorizes specific individuals to act on Lucchese's behalf in matters related to SEC filings, including Forms 3, 4, 5, and 144.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for corporate insiders across all publicly traded companies, including those comparable to Inari Medical such as Penumbra, Boston Scientific, and Medtronic.
• The reporting requirements and timelines are consistent across these companies.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• It ensures compliance with SEC regulations, maintaining investor confidence.

Key Dates